Plain-English translation of NCT06008054 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing three treatment approaches for people with advanced digestive system cancers: alone, combined with , or combined with a . Researchers want to find out which approach works best, what the right doses are, and how safe these treatments are in patients whose cancer has spread or cannot be surgically removed.
Current treatments for advanced digestive cancers don't work well enough for many patients. This trial explores whether these newer medications—some of which work by boosting the immune system—might offer better results and help more people live longer with fewer side effects.
You likely qualify if…
You likely don't qualify if…
You will receive one of three treatment approaches during a 3-week cycle. If you respond well to the medication, you may continue receiving additional treatment cycles as long as the treatment is helping and you are tolerating it well. The trial will monitor you closely for side effects and measure your cancer's response using scans and blood tests. Treatment will stop if your cancer progresses, if you cannot tolerate the medication, or for other medical reasons.
AI-generated summary from trial data · Jun 18, 2026 · Not medical advice
China